Improve health outcomes for your patients with both type 2 diabetes and cardiovascular disease (CVD) by familiarising yourself with the latest CV outcome data and increasing your confidence to navigate management choices for the condition.
This Clinical e-Audit requires data to be submitted for only SEVEN (7) patients.
This program is funded by Boehringer Ingelheim Pty Limited and Eli Lilly Australia Pty Limited and managed through VentureWise, a wholly owned commercial subsidiary of NPS MedicineWise. The program has been designed, developed and implemented by NPS MedicineWise with complete independence and editorial control and is based on best practice guidelines.
RACGP 40 (Category 1) QI and CPD points (QI activity)Toggle information
This activity has been accredited for 40 (Category 1) points (QI activity) in the RACGP QI&CPD Program for the 2017–2019 triennium (activity ID number 139124)
ACRRM 30 PRPD pointsToggle information
This activity has been accredited for 30 PRPD points in the ACRRM PD Program for the 2017–2019 triennium (activity code 13762)
- Recognised for the Practice Incentives Program Quality Prescribing Incentive (PIP QPI)
Over the last few years, the management of type 2 diabetes has become increasingly complex and more challenging. This in part has been due to the introduction of new medicines, updated guidelines and results from emerging cardiovascular outcome trials. This Clinical e-Audit will help you to:
- review your approach to managing CV risk factors for patients with both type 2 diabetes and CVD
- identify and optimise progress towards individual treatment targets (eg, blood pressure, LDL-C and HbA1c)
- use a stepped approach to treatment intensification when glycaemic targets are not being met
- consider emerging evidence from CV outcome trials when recommending treatment.
Our Clinical e-Audits are free quality improvement activities that help GPs review their current prescribing practice for patients with certain conditions, compared with current best practice guidelines.
- completing electronic data collection for 7 patients
- submitting de-identified data securely online
- reflecting on immediate patient-specific feedback to assist implementation of changes to practice
- reviewing individual and peer feedback results, based on achievement of best practice clinical indicators
- recording progress of individual patients automatically identified for review
- reflecting on improvements in your practice.
- Implement intensive cardiovascular risk factor management when treating patients with both type 2 diabetes and established CVD.
- Adopt strategies to promote adherence to blood glucose-lowering medicines.
- Select a blood glucose-lowering medicine based on individual medicine and patient factors.
- Understand the data from new and emerging cardiovascular outcome trials and their relevance to practice.
- have access to a summary of best practice recommendations
- have access to the updated ADS Australian blood glucose treatment algorithm for type 2 diabetes
- receive practical advice to provide to your patients
- create an individualised management plan for each patient
- receive immediate feedback and be able to compare your results with those of your peers.
Expert commentary by Dr Nicholas Forgione
Dr Forgione has been a GP in private practice for approximately 25 years, following a career as Director of Emergency Services at Princess Margaret Hospital for Children and Medical Administrator at Royal Perth Hospital. He has a special interest in all aspects of chronic disease management and medical education as well as child health. He is dedicated to assisting in the provision of continuing peer-to-peer education, especially in the areas of diabetes, obesity, CVD, respiratory disease and osteoporosis, as well as promoting research relevant to general practice. He is currently on several advisory Boards, including Diabetes WA Primary Care Group and the Centre for Clinical Research and Education at Curtin University, is a member of the editorial boards of several medical journals and a member of the RACGP Specific Interest Groups for diabetes and obesity.